PTC Therapeutics (NASDAQ:PTCT) Stock Price Target Raised at Wells Fargo & Company

PTC Therapeutics (NASDAQ:PTCT) had its target price hoisted by Wells Fargo & Company from $109.00 to $112.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective suggests a potential upside of 79.49% from the stock’s previous close.

Other analysts also recently issued reports about the stock. Morgan Stanley increased their price target on shares of PTC Therapeutics from $93.00 to $104.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Cantor Fitzgerald increased their price target on PTC Therapeutics from $130.00 to $137.00 and gave the stock an “overweight” rating in a report on Tuesday, September 22nd. Leerink Partners began coverage on PTC Therapeutics in a research note on Monday, September 14th. They set an “outperform” rating and a $98.00 price objective on the stock. UBS Group began coverage on shares of PTC Therapeutics in a research report on Thursday, October 15th. They set a “buy” rating and a $90.00 target price on the stock. Finally, Weiss Ratings upgraded shares of PTC Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, PTC Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $95.29.

PTC Therapeutics Trading Down 3.2%

PTCT stock traded down $2.06 during midday trading on Friday, reaching $62.40. The company had a trading volume of 963,860 shares, compared to its average volume of 1,345,500. PTC Therapeutics has a 1 year low of $58.80 and a 1 year high of $90.87. The company has a 50 day moving average of $65.57 and a two-hundred day moving average of $70.87. The company has a market capitalization of $5.21 billion, a P/E ratio of -107.21, a PEG ratio of 1.90 and a beta of 0.49.

PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.62) EPS for the quarter, missing the consensus estimate of $0.14 by ($0.76). The company had revenue of $357.81 million during the quarter, compared to analyst estimates of $306.43 million. During the same period last year, the firm posted $0.20 earnings per share. The business’s quarterly revenue was up 69.6% compared to the same quarter last year. On average, sell-side analysts anticipate that PTC Therapeutics will post 1.19 earnings per share for the current year.

Insider Activity at PTC Therapeutics

In other news, VP Mark Boulding sold 2,813 shares of PTC Therapeutics stock in a transaction on Monday, August 17th. The stock was sold at an average price of $72.57, for a total value of $204,139.41. Following the completion of the transaction, the vice president directly owned 105,272 shares in the company, valued at approximately $7,639,589.04. The trade was a 2.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Matthew B. Klein sold 10,292 shares of PTC Therapeutics stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $68.57, for a total value of $705,722.44. Following the sale, the chief executive officer directly owned 383,868 shares of the company’s stock, valued at $26,321,828.76. This represents a 2.61% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 77,370 shares of company stock worth $5,322,261 in the last ninety days. Corporate insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of PTCT. Mirae Asset Global Investments Co. Ltd. purchased a new stake in PTC Therapeutics during the 3rd quarter valued at about $276,000. Profund Advisors LLC grew its holdings in shares of PTC Therapeutics by 56.2% during the third quarter. Profund Advisors LLC now owns 35,877 shares of the biopharmaceutical company’s stock valued at $2,324,000 after buying an additional 12,904 shares during the last quarter. Vise Technologies Inc. grew its position in PTC Therapeutics by 3.1% in the 3rd quarter. Vise Technologies Inc. now owns 8,826 shares of the biopharmaceutical company’s stock worth $572,000 after purchasing an additional 266 shares during the period. State of Wyoming boosted its position in PTC Therapeutics by 15.3% in the third quarter. State of Wyoming now owns 1,962 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 260 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in PTC Therapeutics by 15.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 15,228 shares of the biopharmaceutical company’s stock valued at $989,000 after purchasing an additional 2,027 shares in the last quarter.

Key Stories Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: PTC reported third-quarter revenue of approximately $358 million, up 69.6% year over year and above the roughly $306 million consensus estimate. Product revenue was $276 million, led by Sephience (sepiapterin), which generated $182 million as U.S. adoption and international expansion continued. PTC Therapeutics Third-Quarter Results
• Positive Sentiment: Management raised its 2026 outlook, now expecting total revenue of $1.29 billion to $1.32 billion and product revenue of $960 million to $990 million. The upgrade signals confidence in Sephience’s commercial momentum and the broader product portfolio. PTC Therapeutics Raises 2026 Outlook
• Positive Sentiment: PTC acquired ST-920, a Fabry disease gene therapy, and expects to complete its Biologics License Application submission in the fourth quarter of 2026. The deal adds a potential late-stage growth asset, although regulatory and development execution remain important risks. PTC Corporate Update
• Negative Sentiment: Reported profitability was mixed. PTC posted a GAAP loss of $0.62 per share, well below the consensus estimate for $0.14 of earnings, even though an adjusted earnings measure cited by Zacks was $0.61 per share and above estimates. The conflicting measures may have contributed to investor caution. PTC Swings to Third-Quarter Loss
• Neutral Sentiment: The earnings call focused on Sephience’s launch trajectory, global expansion, the ST-920 acquisition and the updated 2026 outlook. Investors will likely monitor whether revenue growth translates into sustainable earnings and cash flow. PTC Q3 2026 Earnings Call Transcript

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs include small-molecule treatments, gene therapies and other approaches designed to address conditions with limited or no available treatment options.

The company’s commercial portfolio has included Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy authorized in the European Union for aromatic L-amino acid decarboxylase deficiency.